His-bundle pacing and atrioventricular nodal ablation for noncontrolled atrial arrhythmia: A technical challenge with

Corentin Chaumont1, Nathanael Auquier2, Antoine Milhem3

  • 1Department of Cardiology, Rouen University Hospital, Rouen, France; FHU REMOD-VHF, UNIROUEN, INSERM U1096, Rouen, France.

Heart Rhythm
|December 22, 2022
PubMed

Insights

His-bundle pacing (HBP) combined with atrioventricular nodal ablation (AVNA) is a feasible and effective treatment for uncontrolled atrial arrhythmias. This approach preserves physiological activation and improves patient outcomes, with lead placement crucial for success.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • His-bundle pacing (HBP) offers physiological ventricular activation, an advantage over traditional right ventricular pacing.
  • Limited data exist on the combination of HBP and atrioventricular nodal ablation (AVNA).

Purpose of the Study:

  • To evaluate the feasibility and efficacy of AVNA combined with HBP in patients with uncontrolled atrial arrhythmias.
  • To provide further evidence supporting this therapeutic strategy.

Main Methods:

  • Prospective study of 75 patients undergoing AVNA after HBP implantation across three hospitals (2017-2022).
  • Assessment of AVNA success rates (complete block or rate control) and His-bundle (HB) lead performance.
  • Evaluation of lead stability and HB capture thresholds post-procedure.

Main Results:

  • Successful AVNA achieved in 77% (complete block) and 16% (rate control) of patients.
  • No lead dislodgments occurred; acute HB capture threshold increases were transient in most cases.
  • Significant improvements observed in New York Heart Association functional class and left ventricular ejection fraction.

Conclusions:

  • AVNA combined with HBP is a feasible and clinically effective treatment for uncontrolled atrial arrhythmias.
  • Optimal HB lead placement, avoiding atrial signal recording, can enhance AVNA success.
Abstract

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
28
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.1K
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
19
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
814
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
933
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
73